Pharm

Marijuana: a green grey zone for patients, doctors, and pharma companies

Marijuana: a green grey zone for patients, doctors, and pharma companies

By

Legalization of the drug for medical use is already having an impact on prescription patterns. But for patients and doctors alike, there are a lot of unanswered questions.

Marketers Trend Report 2018: Relief after one year of Trump doesn't mitigate all concerns

Marketers Trend Report 2018: Relief after one year of Trump doesn't mitigate all concerns

By

The general sense: Nobody should get comfortable with the status quo

GSK prepares for Advair competition

GSK prepares for Advair competition

By

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.